Suzanne Farid
Professor Suzanne Farid CBE FREng FIChemE is an engineer who specialises in Biochemical and Systems Engineering. She is a professor of bioprocess systems engineering and head of the Department of Biochemical Engineering at University College London (UCL). Her work focuses on monoclonal antibodies and their use in cell and gene therapies.
Farid joined UCL as a lecturer in 2001 after completing her PhD there. In 2007 she published a paper on cost‑effective antibody manufacturing in the Journal of Chromatography. A 2012 paper in Biotechnology and Bioengineering looked at batch and continuous cell culture technologies and their commercial potential, including a case study on monoclonal antibodies.
In 2020 she and lead author Maria Papathanasiou published a Nature paper on using T cells as a cancer therapy in the future. Her expertise led to involvement in the UK government’s COVID‑19 response as a member of the 100 Days Mission roundtable, and she was frequently interviewed about vaccine development. She is the Director of the UCL‑AstraZeneca Bioprocessing Centre of Excellence and co‑director of the Future Targeted Healthcare Manufacturing Hub, funded by the EPSRC. In 2022 she was elected a fellow of the Royal Academy of Engineering.
This page was last edited on 2 February 2026, at 13:23 (CET).